Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Free Cash Flow: 2022-2025

Historic Free Cash Flow for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -$14.1 million.

  • Phathom Pharmaceuticals' Free Cash Flow rose 77.77% to -$14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$225.4 million, marking a year-over-year increase of 9.02%. This contributed to the annual value of -$266.9 million for FY2024, which is 91.72% down from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Free Cash Flow of -$14.1 million as of Q3 2025, which was up 77.48% from -$62.8 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Free Cash Flow ranged from a high of -$14.1 million in Q3 2025 and a low of -$85.0 million during Q1 2025.
  • For the 3-year period, Phathom Pharmaceuticals' Free Cash Flow averaged around -$51.6 million, with its median value being -$62.8 million (2025).
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 218.68% in 2024, then soared by 77.77% in 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' Free Cash Flow (Quarterly) stood at -$41.5 million in 2022, then decreased by 6.80% to -$44.3 million in 2023, then plummeted by 43.34% to -$63.5 million in 2024, then spiked by 77.77% to -$14.1 million in 2025.
  • Its Free Cash Flow was -$14.1 million in Q3 2025, compared to -$62.8 million in Q2 2025 and -$85.0 million in Q1 2025.